Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director

Regulations by 2FIRSTS, edited by Sophia
May.06.2024
Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Recent announcements from Jinjia Corporation (002191) reveal lifted restrictions on Qiao Luyu but investigation and detention of Li Dehua.

Recently, listed company Jinjia Group (002191) on the Shenzhen Stock Exchange has issued a series of announcements. Firstly, the disciplinary commission in Enyang District, Bazhong City has lifted the detention measures against Qiao Luyu. Secondly, the company's director and deputy general manager, Li Dehua, has been placed under investigation and detained.

 

According to relevant documents issued by the Supervision Committee of Enyang District, Bazhong City, the actual controller and chairman of the company, Qiao Luyu, is under investigation and has been placed under detention. On April 27, 2024, the company received a notice from the Supervision Committee of Enyang District, Bazhong City, lifting the detention of Qiao Luyu (Enjianjie Lutong [2024] No. 2), indicating that the Supervision Committee of Enyang District, Bazhong City has lifted the detention measures against Qiao Luyu. Currently, Qiao Luyu is able to carry out his duties as the chairman and legal representative of the company as normal, and the company's director and general manager, Hou Xudong, no longer acts on behalf of the company's chairman and legal representative.

 

Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Announcement | Image source: Jincare Group

 

On May 1st, the company received a notification from the Jinzhou District Supervisory Committee in Dalian City regarding the investigation and detention of the company's director and deputy general manager, Li Dehua.

 

Jinjia Group: Restrictions Lifted on Controller, Investigation and Detention on Director
Announcement | Image Source: Jincar Group

 

Jiangjia Group stated that the company has a sound governance structure and internal control mechanism, operating in compliance with laws, regulations, and rules such as the Company Law, the Shenzhen Stock Exchange Listing Rules, the Corporate Governance Guidelines for Listed Companies, and the company's articles of association. The company has already made proper arrangements for the work related to Li Dehua, and the ongoing investigation will not have a significant impact on the company's daily operations. All production and operational activities of the company are proceeding as usual.

 

Jinjia Corporation stated that as of the date of this announcement, the company is not aware of the progress and conclusion of the investigation. The company will continue to monitor the developments of the investigation and adhere to relevant laws and regulations, fulfill its disclosure obligations in a timely manner, and alert of any related risks.

 

According to the 2023 annual report of Jinjia Group, Li Dehua was born in 1968, is of Chinese nationality, does not have permanent residency abroad, has a high school education, and has been employed by Jinjia Group since 1996. He currently serves as a director, executive deputy general manager, and general manager of the production and marketing branch of the company, as well as holding other positions such as executive director of Shenzhen Qianhai Blueberry Culture Communication Co., Ltd. In 2023, Li Dehua received a total pre-tax compensation of 2.361 million yuan from the company.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
HM Revenue & Customs put the UK's Vaping Products Duty and Vaping Duty Stamps Scheme into effect on October 1. All vaping liquids manufactured in or imported into the UK are now subject to duty at £2.20 per 10ml, regardless of nicotine content. The stamp regime will introduce digital functionality designed to provide traceability throughout the supply chain, with approved manufacturers, importers and warehousekeepers required to report product movements and retailers and consumers eventually able to scan stamps to verify authenticity. China exported $177 million of vape-related products to the UK in August, up 51.4% year over year, increasing the significance of the new compliance regime for China's Shenzhen-centered vape supply chain.
Regulations
Oct.04
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands Acquires Helwit Owner Yoik Group for SEK 515 Million, More Than Doubling Swedish Nicotine Pouch Share
Imperial Brands has agreed to acquire 100% of Swedish modern oral nicotine company Yoik Group AB for an initial SEK515 million, equivalent to about US$53.9 million, plus a deferred payment linked to performance over the next two years. Yoik owns nicotine pouch brand Helwit, which held about 3.4% of Sweden’s modern oral nicotine market over the past 12 months. Imperial says the acquisition will more than double its existing share of the Swedish market. Helwit is also sold elsewhere in the Nordics, through European online channels and in selected UK retail outlets.
Sep.08
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
NAS 2026 | Cliff Douglas: Risk Continuum Should Play a Central Role in Tobacco Policy
Cliff Douglas, a veteran U.S. tobacco-control and public health policy figure, told NAS 2026 that the “continuum of risk” should play a central role in tobacco policy. He called for clearer market pathways, stronger risk communication, differentiated regulation and enforcement, and said possible FDA reforms to PMTA reviews could be a “welcome correction” if they create a more efficient, predictable route for scientifically substantiated lower-risk products. Read 2Firsts’ on-site coverage.
Sep.26